Analgesics and Anti-inflammatory Drugs Practice Questions

Q: Acute gouty arthritis is seen early in treatment following which medication?

All of the above. **Explanation:** The paradoxical precipitation of an **acute gouty attack** during the initiation of urate-lowering therapy (ULT) is a classic pharmacological phenomenon. This occurs due to the rapid fluctuation in serum uric acid levels, which leads to the mobilization and "shedding" of urate crystals from tissue stores (tophi) into the joint space, triggering an inflammatory response. **Breakdown of Options:** * **Allopurinol (Option B):** As a Xanthine Oxidase inhibitor, it lowers uric acid production. Rapid reduction in serum levels causes existing crystals to dissolve and fragment, precipitating acute inflammation. * **Probenecid (Option A):** This is a uricosuric agent that increases renal excretion of uric acid. Like Allopurinol, the sudden drop in serum urate can trigger a flare. * **Rasburicase (Option C):** This is a recombinant urate oxidase enzyme that rapidly converts uric acid into the highly soluble allantoin. Because it lowers uric acid levels much more aggressively than oral drugs, the risk of a flare is significant. **Why "All of the Above" is Correct:** Any drug that significantly alters the concentration of uric acid in the blood—whether by decreasing production (Allopurinol), increasing excretion (Probenecid), or direct metabolism (Rasburicase)—can destabilize intra-articular crystals and cause an acute attack early in treatment. **NEET-PG High-Yield Pearls:** * **Prophylaxis:** To prevent these early flares, ULT should always be co-administered with low-dose **Colchicine** or **NSAIDs** for the first 3–6 months. * **Timing:** Never start ULT during an ongoing acute attack; wait 2 weeks after the attack resolves. However, if a patient is already on ULT and an attack occurs, do **not** stop the medication. * **Drug of Choice:** Allopurinol is the first-line ULT for chronic gout, but **Febuxostat** is an alternative for those with renal impairment.

Q: Which of the following is an uricosuric drug?

Probenecid. **Explanation:** **Probenecid** is the correct answer because it is a classic **uricosuric agent**. Its primary mechanism of action involves the inhibition of the **URAT1 transporter** in the proximal convoluted tubule of the kidney. By blocking the reabsorption of filtered uric acid back into the blood, it increases the renal excretion of uric acid, thereby lowering serum urate levels. It is used in the chronic management of gout in patients who are "underexcretors." **Analysis of Incorrect Options:** * **Allopurinol (Option A):** This is a **Xanthine Oxidase inhibitor**. It reduces the *production* of uric acid rather than increasing its excretion. It is the first-line drug for chronic gout but is not classified as uricosuric. * **Indomethacin (Option B):** This is a potent **NSAID**. It is used to treat the *inflammation and pain* during an acute gouty attack but has no direct effect on uric acid levels or excretion. * **Aspirin (Option D):** At standard analgesic doses, aspirin actually **inhibits** uric acid excretion (hyperuricemic) and can worsen gout. While very high doses (>5g/day) are uricosuric, it is never used for this purpose due to toxicity. **High-Yield Clinical Pearls for NEET-PG:** * **The "Aspirin Paradox":** Low-dose aspirin (1-2g/day) causes urate retention; high-dose aspirin (>5g/day) is uricosuric. * **Drug Interaction:** Probenecid inhibits the renal secretion of **Penicillin**, prolonging its half-life—a fact historically used to conserve penicillin supplies. * **Contraindication:** Uricosurics should be avoided in patients with a history of **renal stones** (nephrolithiasis) to prevent stone formation in the urinary tract. * **Other Uricosurics:** Sulfinpyrazone and Lesinurad. Benzbromarone is another potent uricosuric often mentioned in exams.

Q: A patient with a history of peptic ulcer disease presents with arthritis and develops carditis. Which of the following is the most appropriate anti-inflammatory drug?

Celecoxib. ***Celecoxib***- Celecoxib is a **selective COX-2 inhibitor**, meaning it primarily blocks the enzyme responsible for inflammation while largely preserving **COX-1** activity, which is crucial for gastric mucosal protection [2].- This selectivity significantly reduces the risk of **peptic ulcers** and gastrointestinal bleeding, making it the safest NSAID choice for patients with a history of **Peptic Ulcer Disease** (PUD) requiring treatment for arthritis and carditis [1].- **Note**: While COX-2 inhibitors carry cardiovascular risk warnings, in this clinical scenario (likely **rheumatic carditis** requiring anti-inflammatory therapy), celecoxib offers the best **risk-benefit profile** among NSAIDs by minimizing GI complications in a PUD patient [3]. Close cardiac monitoring is advised.*Ibuprofen*- Ibuprofen is a **non-selective NSAID** that inhibits both COX-1 and COX-2, leading to effective anti-inflammatory effects but also significant risk of **gastrointestinal (GI) toxicity**.- Inhibition of **COX-1** impairs the synthesis of protective mucosal prostaglandins, posing a high risk of ulcer recurrence or bleeding in patients with a PUD history [4].*Diclofenac*- Diclofenac is also a **non-selective NSAID** which carries a considerable risk of GI side effects by inhibiting **COX-1**, making it generally unsuitable for patients with pre-existing PUD.- Although sometimes exhibiting relative COX-2 preference compared to agents like naproxen, the GI risk remains high enough to warrant the use of a true COX-2 selective inhibitor like celecoxib in this high-risk patient [2].*Naloxone*- Naloxone is an **opioid receptor antagonist** used primarily to reverse the effects of opioid overdose; it has no **anti-inflammatory** properties.- This medication is completely irrelevant to the underlying inflammatory condition (arthritis and carditis) and the need for **pain and inflammation control**.

Q: A patient with osteoarthritis, for the last 3 months, has been taking ibuprofen and has developed occult GI bleeding. Which is correct about the cause?

PGE-2 and prostacyclin production were reduced. ***PGE-2 and prostacyclin production were reduced***- NSAIDs like **ibuprofen** inhibit cyclooxygenase-1 (**COX-1**), which is responsible for synthesizing protective prostaglandins like **PGE2** and **prostacyclin (PGI2)** in the GI mucosa.- The loss of these protective factors impairs the mucosal barrier's ability to withstand acid, leading to ulceration, erosion, and subsequent **occult GI bleeding**. *Increased acid production*- NSAIDs primarily cause mucosal injury by reducing protective factors, not by significantly increasing **basal acid production**.- Although excess acid facilitates damage, the core mechanism of NSAID injury is the loss of **prostaglandin-mediated cytoprotection**. *PGE-1 and prostacyclin production were reduced*- While **prostacyclin (PGI2)** reduction is key, **PGE2** (not PGE1) is the major endogenous prostaglandin responsible for maintaining gastric mucosal integrity in humans.- Misrepresenting the primary protective prostaglandin (PGE2 vs PGE1) makes this option medically less precise than the former. *Mucosal injury due to inhibition of COX-2*- The severe gastrointestinal side effects, including bleeding and ulceration, are predominantly due to the inhibition of the constitutive **COX-1 isoenzyme**.- Selective **COX-2 inhibitors** (coxibs) were specifically designed to minimize GI toxicity by sparing the protective functions of COX-1.

Q: Which of the following drugs increases uric acid in urine?

Probenecid. ***Probenecid***- This drug is a **uricosuric agent** that works by inhibiting the reabsorption of urate at the **proximal convoluted tubule** of the kidney.- By blocking reabsorption, **probenecid** promotes the excretion of uric acid into the urine, thereby reducing serum uric acid levels.*Colchicine*- *Colchicine* is primarily used for the management of **acute gout flares** and works by inhibiting neutrophil migration and subsequent inflammatory responses.- It does **not** significantly alter the renal handling of uric acid; therefore, it does not increase uric acid excretion in the urine.*Febuxostat*- *Febuxostat* is a **non-purine selective inhibitor of xanthine oxidase**, an enzyme required for uric acid synthesis.- Its mechanism is to **decrease the production** of uric acid by the body, thus lowering serum levels, rather than promoting its excretion in the urine.*Allopurinol*- *Allopurinol* is a **purine analog and a xanthine oxidase inhibitor** used for the prophylactic management of chronic gout.- Like Febuxostat, it acts to **decrease the synthesis** (production) of uric acid, contrasting with uricosuric agents which increase excretion.

Q: A patient with tumor lysis syndrome has elevated uric acid levels. What is the mechanism of action of pegloticase?

Oxidises uric acid. ***Oxidises uric acid*** - Pegloticase is a recombinant pegylated uricase enzyme that directly catalyzes the conversion of highly insoluble **uric acid**. - It oxidizes uric acid into **allantoin**, which is a highly soluble compound easily excreted by the kidneys, effectively lowering serum uric acid levels. *Xanthine oxidase inhibition* - This is the mechanism of action for drugs like **allopurinol** and **febuxostat**, used to prevent the formation of uric acid. - These agents act upstream by inhibiting the enzyme responsible for synthesizing uric acid from xanthine and hypoxanthine. *URAT1 receptor inhibition* - URAT1 inhibitors (**lesinurad**) prevent the reabsorption of native uric acid from the renal tubules back into the bloodstream. - This mechanism is characteristic of **uricosuric agents**, which increase the renal clearance of uric acid. *Excretion of uric acid* - While pegloticase ultimately facilitates excretion (as allantoin), this option is too broad; its primary action is **enzymatic conversion**. - Direct excretion of native uric acid is increased by **uricosuric drugs** (e.g., probenecid), not by pegloticase's oxidative action.

Q: A patient presents with swelling in MCP joints, and his serum uric acid levels were found to be elevated. His physician prescribed a drug which is considered as the first line agent in the management of this condition. What is the mechanism of this drug?

Xanthine oxidase inhibitor. ***Xanthine oxidase inhibitor*** - The presentation of **swollen MCP joints** and **elevated uric acid** is highly suggestive of **gout**. - **Allopurinol**, a **xanthine oxidase inhibitor**, is the **first-line drug** for chronic gout management, reducing uric acid production. *Uricosuric drug* - **Uricosuric agents** like **probenecid** increase uric acid excretion, but they are generally **second-line** or used in specific cases, not first-line for most patients. - These drugs are typically only effective if there is **sufficient renal function** and are contraindicated in patients with a history of **kidney stones**. *Pyrimidine antimetabolite* - **Pyrimidine antimetabolites** like **5-fluorouracil** are primarily used in **chemotherapy** for certain cancers by interfering with DNA and RNA synthesis. - They have **no role** in the treatment of gout or hyperuricemia. *Inhibitor of neutrophil recruitment* - **Colchicine**, which inhibits neutrophil migration, is used to treat **acute gout flares** by reducing inflammation, but it's not the first-line agent for **long-term management** of hyperuricemia. - This mechanism targets the inflammatory response rather than the underlying **uric acid production** or excretion.

Q: What is the mechanism of action of cyclosporine?

Inhibition of calcineurin. ***Inhibition of calcineurin*** - Cyclosporine forms a complex with **cyclophilin**, which then inhibits the phosphatase activity of **calcineurin**. - This inhibition prevents the dephosphorylation and subsequent nuclear translocation of **NFAT (nuclear factor of activated T-cells)**, thereby blocking the transcription of **IL-2** and other cytokines essential for T-cell activation. *Dihydro-orotate dehydrogenase inhibition* - This is the mechanism of action of **leflunomide**, another immunosuppressant, which works by inhibiting *de novo* pyrimidine synthesis. - Leflunomide primarily affects rapidly proliferating cells, such as T-lymphocytes, by depriving them of essential pyrimidine nucleotides. *AMP kinase stimulation* - **AMP-activated protein kinase (AMPK)** is a cellular energy sensor that plays a role in metabolism and cellular growth. - While AMPK activation has various cellular effects, it is not the primary mechanism of action for cyclosporine or other calcineurin inhibitors. *IMP dehydrogenase inhibition* - This is the mechanism of action of **mycophenolate mofetil**, an immunosuppressant that selectively inhibits *de novo* guanosine nucleotide synthesis. - By depleting guanosine nucleotides, mycophenolate specifically inhibits the proliferation of T and B lymphocytes.

Question 1

Gastric irritation is least with which of the following NSAIDs?

Accepted Answer

Acetaminophen

Answer

Diclofenac

Answer

Ibuprofen

Answer

Naproxen

Question 2

Acute gouty arthritis is seen early in treatment following which medication?

Accepted Answer

All of the above

Answer

Probenecid

Answer

Allopurinol

Answer

Rasburicase

Question 3

Which of the following is an uricosuric drug?

Accepted Answer

Probenecid

Answer

Allopurinol

Answer

Indomethacin

Answer

Aspirin

Question 4

A patient with a history of peptic ulcer disease presents with arthritis and develops carditis. Which of the following is the most appropriate anti-inflammatory drug?

Accepted Answer

Celecoxib

Answer

Diclofenac

Answer

Naloxone

Answer

Ibuprofen

Question 5

A patient with osteoarthritis, for the last 3 months, has been taking ibuprofen and has developed occult GI bleeding. Which is correct about the cause?

Accepted Answer

PGE-2 and prostacyclin production were reduced

Answer

PGE-1 and prostacyclin production were reduced

Answer

Increased acid production

Answer

Mucosal injury due to inhibition of COX-2

Question 6

Which of the following drugs increases uric acid in urine?

Accepted Answer

Probenecid

Answer

Allopurinol

Answer

Colchicine

Answer

Febuxostat

Question 7

A patient with tumor lysis syndrome has elevated uric acid levels. What is the mechanism of action of pegloticase?

Accepted Answer

Oxidises uric acid

Answer

Urat-1 receptor inhibition

Answer

Xanthine oxidase inhibition

Answer

Excretion of uric acid

Question 8

A 60 -year-old patient of carcinoma prostate is having skeletal metastasis. He was put on 8 mg of hydromorphone daily but is still having severe bone pain. He was then put on the transdermal system shown below. All are correct about this transdermal system except:

Accepted Answer

Put the new patch at the same site to prevent skin sensitization

Answer

Exposure to heat can result in overdose

Answer

Respiratory depression is a chief hazard

Answer

Abuse liability similar to opioids

Question 9

A patient presents with swelling in MCP joints, and his serum uric acid levels were found to be elevated. His physician prescribed a drug which is considered as the first line agent in the management of this condition. What is the mechanism of this drug?

Accepted Answer

Xanthine oxidase inhibitor

Answer

Uricosuric drug

Answer

Pyrimidine antimetabolite

Answer

Inhibitor of neutrophil recruitment

Question 10

What is the mechanism of action of cyclosporine?

Accepted Answer

Inhibition of calcineurin

Answer

Dihydro-orotate dehydrogenase inhibition

Answer

AMP kinase stimulation

Answer

IMP dehydrogenase inhibition

Analgesics and Anti-inflammatory Drugs — MCQs

Analgesics and Anti-inflammatory Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?